|
Automated Blood Sampling and Analysis Platform: Cascade Metrix, Inc. has innovated upon an automated vascular blood sampling system ("AutoSam pler") that is designed to enable increased adoption of multiple POC medical diagnostic applications currently constrained by workflow challenges stemming from manual blood sampling methods. To obtain a rapid blood analysis, a specimen is either rushed to a laboratory for an in vitro “stat” determination or it is tested at the “point-of care” with a portable analyzer or hand-held device. CMI will soon introduce a revolutionary ex-vivo blood analysis system. The AutoSampler automatically samples micro-liter quantities of whole blood from a patient and performs frequent measurements of various blood constituents. The CMI system introduces a whole new paradigm in patient monitoring that will both optimize nursing efficiency and improve patient care. The platform is enabling the commercialization of several products:
- Novel Micro-volume IV Extension Kits: This product will be an early revenue Generator in the $1.5B IV Catheter Market. The extension kit lowers the blood loss per draw by an order of magnitude (from current 3-5ml to 0.3-0.5ml with proposed set). The extension kit consists of specialized zero dead volume snap-on luer, a self-sealing aseptic quick release mechanism that eliminates the need for manual pinch valves, smooth pressure-relieving external contours on the luer and quick release, and a small bore specialized kink resistant tubing with see-through fluidic components.
- Automated Glucose Monitoring System: The CMI system is being applied to the automated measurement of blood glucose in hospitalized patients. The system performs automated/on-demand blood glucose monitoring in a safe, efficient and cost effective manner. The system includes a durable unit and a disposable catridge consisting of the AutoSampler tube-set and the glucose sensor module. The CMI system automatically withdraws a tiny blood sample from the patient’s IV line without compromising blood sterility and performs a blood glucose test. All blood contaminated material is fully contained within the cartridge. Through the user interface, audible and visual alarms can be set and trends can be continuously displayed or instantly recalled. All measurement data can also be uploaded to the hospital’s electronic medical record system. The CMI system uses the same conventional electrochemical glucose sensor technology that is proven as safe, effective, and accurate in multiple products used in the hospitals for manual blood glucose testing. The CMI prototype system has already been successfully validated on human subjects. CMI expects to file a 510(k) pre-market notification with the FDA in Q2 of 2012 and to begin commercial product shipments following government clearance.
- Other Analytes: CMI plans to add other time sensitive tests to the AutoSampler platform. Whole blood sensors to monitor sepsis, heparin therapy, blood gases, electrolytes and certain biomarkers will be integrated to the CMI sampling platform. Combining leading edge innovations in micro-fluidics, electro-chemistry, and machine intelligence, CMI has developed patentable inventions covering technologies, designs, and other relevant operational aspects.
CAUTION: Investigational device, limited by federal law to investigational use.
Device shown is for illustration purposes only
|
